NCT03078959

Prognostic Value of PD-L1 in NSCLC

The Prognostic Value of the Expression of Programmed Death Ligand 1 (PD-L1) in Early Stage Non-small-cell Lung Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 350 (actual)
• Sponsor: Fondazione Ricerca Traslazionale · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an observational retrospective study. The primary objective is to investigate the expression and potential prognostic role of Programmed Death Ligand 1 (PD-L1) in tumor samples from 350 patients with early stage treatment-naive non-small-cell lung cancer (NSCLC). Tissue samples were embedded in a tissue microarray. PD-L1 will be studied by immunohistochemistry using the SP263 antibody. Stained samples will be evaluated independently by two operators. A tumor will be defined as positive when = or \>50% of tumor cells express the ligand. The investigators will investigate the relationship between PD-L1 protein expression and overall survival and other clinical characteristics with appropriate statistical methods.

Conditions

• Carcinoma, Non-Small-Cell Lung

Interventions

Type	Name	Description
OTHER	immunohistochemistry	Samples will be stained using the SP263 antibody clone against PD-L1

Timeline

• Start date: 2017-03-03
• Primary completion: 2017-03-30
• Completion: 2017-04-15
• First posted: 2017-03-14
• Last updated: 2017-03-14